Taiho Oncology Advances Zipalertinib in Phase 3 Trial
Princeton, New Jersey, Tokyo, Japan & Cambridge, Massachusetts, August 12, 2026 Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Princeton, New Jersey, Tokyo, Japan & Cambridge, Massachusetts, August 12, 2026 Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced...
